| abstract |
The present invention relates to bifunctional compounds that inhibit tau protein and / or promote targeted ubiquitination for degradation of tau protein. In particular, the invention relates to compounds that can bind to tau protein, a protein whose aggregation is involved in a variety of neurodegenerative diseases (e.g., <i />, tauopathies), and may promote its degradation by recruitment an E3 ubiquitin ligase (e.g. <i /> Cereblon), which can ubiquitinate the tau protein, labeling it for proteosomal degradation. The present invention also relates to radiolabeled forms of bifunctional compounds, pharmaceutical compositions comprising bifunctional compounds, methods for detecting and / or diagnosing neurological disorders, methods for detecting and / or diagnosing a pathological aggregation of the protein tau (e.g., <i />, in the central nervous system), methods of treating and / or preventing neurological disorders, and methods of promoting degradation of tau protein by E3 ubiquitin activity ligase in a subject by administering a compound or a composition according to the present invention. |